Brief: Evelo Biosciences Inc - Co Announced Planned Updates To The Study Protocol For Its Phase 2 Clinical Trial Of EDP1815 In Atopic Dermatitis

Evelo Biosciences

22/12/2021 22:07

Dec 22 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES INC - CO ANNOUNCED PLANNED UPDATES TO
THE
STUDY PROTOCOL FOR ITS PHASE 2 CLINICAL TRIAL OF EDP1815 IN
ATOPIC DERMATITIS
    * EVELO BIOSCIENCES INC - DECIDED TO INCREASE NUMBER OF
PARTICIPANTS IN PHASE 2 CLINICAL TRIAL OF EDP1815 TO 300, EXTEND
THE DOSING PERIOD TO 16 WEEKS
    * EVELO BIOSCIENCES-TO REDUCE LOWEST DOSE TO BE INVESTIGATED
IN
PHASE 2 ATOPIC DERMATITIS TRIAL
    * EVELO BIOSCIENCES INC - TO EVALUATE EDP1815 DRUG SUBSTANCE
PRODUCED USING 2 DIFFERENT MAKING PROCESSES IN PHASE 2 TRIAL
    * EVELO BIOSCIENCES- BASED ON PLANNED CHANGES TO STUDY
PROTOCOL,
DOSING FOR PHASE 2 ATOPIC DERMATITIS TRIAL EXPECTED TO BEGIN IN
Q1 OF 2022
    * EVELO BIOSCIENCES INC - RESULTS FROM PHASE 2 ATOPIC
DERMATITIS
TRIAL ANTICIPATED IN THE FIRST HALF OF 2023

Source text for Eikon:  ID: 
Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))